{"a":[{"_":"Elevar wins FDA nod for bile duct cancer drug Lyrfigtu, a first for a Korean firm","$":{"href":"/pharma/elevar-wins-fda-nod-bile-duct-cancer-drug-lyrfigtu-first-korean-company","hreflang":"en"}}]}
RegulatoryapprovedLyrfigtuPositive
AI Analysis
Summary
Elevar's Lyrfigtu, an FGFR2-selective inhibitor, has received FDA approval for bile duct cancer treatment, marking the first novel cancer drug from a Korean company to achieve FDA approval.
Outcome Details
FDA approval for FGFR2-selective inhibitor in bile duct cancer; first novel cancer drug from a Korean company to receive FDA approval
Importance:8/10
Sentiment:
0.95
FDA approvaloncologyKoreafirst-to-marketFGFR2 inhibitor
Read the original article
Published by FiercePharma on September 24, 2026 10:49 AM